Company Information

  

Address: 3 FORBES ROAD  
City: LEXINGTON 
State: MA 
Zip Code: 02421 
Telephone: 781-674-4410 

Description of Business

Primary SIC Code: 2836
(As filed with the SEC)  

We are a clinical-stage immuno-oncology ("I-O") company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. Our approach to cancer immunotherapy involves a diverse portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. We, in collaboration with our partners, have developed a number of immuno-modulatory antibodies against important nodes of immune regulation. These include antibodies targeting CTLA-4, GITR and OX40 that are in clinical development, and our anti-PD-1 antibody anticipated to enter the clinic in the first half of 2017. Our discovery pipeline includes a number of proprietary checkpoint modulating ("CPM") antibodies against innovative targets such as TIGIT and 4-1BB (also known as CD137). We believe that tailored combination therapies are essential to combat some of the most resistant cancers.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-1.28NAN/E
03/2017-1.27NAN/E
12/2016-1.46NAN/E
09/2016-1.34NAN/E
06/2016-0.99NAN/E
03/2016-1.22NAN/E
12/2015-1.13NAN/E
09/2015-1.38NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.15Total Liab/Total Assets1.25
Net Inc/Total Assets-0.81Total Liab/Inv Cap1.69
Net Inc/Inv Cap-1.09Total Liab/Comm Equity0.23
Pretax Inc/Net Sales-5.63Interest Coverage Ratio-6.33
Net Inc/Net Sales-5.63Curr Debt/Equity0.00
Cash Flow/Net Sales-3.54LTD/Equity-3.34
SG&A/NetSales1.55Total Debt/Equity-3.34
Asset Utilization   Liquidity  
Net Receivables Turnover2.13Quick Ratio2.23
Inventory TurnoverNACurrent Ratio2.24
Inventory Day SalesNANet Rec/Curr Assets0.12
Net Sales/Work Cap0.45Inv/Curr Assets0.00
Net Sales/PP&E0.88  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) 4.21 26.96 5.58 4.45
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 7.27 7.57 -0.73 19.08
Operating Income -28.89 -13.26 -19.68 -36.22
Interest Exp 4.47 4.59 4.57 4.41
Pretax Income -31.71 -17.10 -26.12 -40.77
Other Income 1.65 0.74 -1.88 -0.14
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -31.71 -17.10 -26.12 -40.77

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 96.77 123.82 76.44 95.40
Receivables - Total 3.94 6.77 11.35 10.28
Inventories - Total 0.09 0.09 0.09 0.09
Total Current Assets 110.69 137.95 91.31 109.53
Net Property, Plant & Equipment 25.58 25.46 25.63 23.51
Total Assets 176.49 203.27 156.99 174.84
Liabilities        
Accounts Payable 25.14 27.28 33.30 24.80
Debt in Current Liabilities 0.15 0.15 0.15 0.15
Total Current Liabilities 32.91 36.35 40.85 34.85
Long-Term Debt 138.53 134.16 130.54 126.26
Total Liabilities 193.97 194.36 196.11 195.88
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 1.00 0.99 0.88 0.87
Retained Earnings -954.60 -923.64 -905.33 -879.21
Treasury Stock NA NA NA NA
Total Stockholders' Equity -17.48 8.90 -39.13 -21.04
Total Liabilities and Stockholders' Equity 176.49 203.27 156.99 174.84

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -27.38 -14.83 -16.12 -23.82
Net Cash Provided by Investing Activities -5.96 -5.26 10.67 24.98
Net Cash Provided by Financing Activities 1.29 62.07 2.19 0.57

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/201215.96-11.32-0.51
12/20133.05-30.07-1.12
12/20146.98-42.49-0.71
12/201524.82-87.88-1.13
12/201622.57-127.00-1.46
Growth Rates9.05----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/1712139,40339.52




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.